Status
Conditions
About
Background:
Objectives:
Eligibility:
Design:
Full description
Mycobacterium tuberculosis (MTB) is a slow-growing bacterium that establishes latent infection in millions of persons worldwide, but only leads to disease in 10% or less of these individuals. It typically causes pneumonia, however dissemination to almost any other organ is possible. Drug resistance of the organism, co-infection with HIV, and paradoxical reactions upon treatment are all factors that may complicate treatment.
Host defense against mycobacterial infections is important. Specific defects within the innate immune system lead to Mendelian susceptibility to mycobacterial infections. HIV infected individuals and persons treated with anti-tumor necrosis factor antibodies are highly susceptible to tuberculosis (TB) infection. Genetic influence on susceptibility to TB disease is complex and does not seem to be confined to a single gene or pathway.
Advancement in molecular techniques has expanded our understanding of the pathogenesis and epidemiology of MTB. Identification of gene mutations that confer antibiotic resistance are being exploited as alternatives to conventional drug susceptibility testing.
The natural history of all forms of TB disease (including co-infection with HIV and other infections) will be followed, and MTB isolates and blood from 100 infected patients will be obtained in order to study organism virulence and host immune function and genetic/epigenetic factors. While it is recognized that the number of TB cases that occur in the Washington, DC area and nationally is low, it is imperative that a mechanism is in place to evaluate and treat these patients at the NIH Clinical Center. This protocol will also allow NIH infectious diseases trainees to manage challenging cases of TB.
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
FOR ALL PATIENTS
Patients may be included in this study who:
FOR PATIENTS WITH LATENT TB
In addition to the above-described inclusion criteria for all patients, patients may be included in the Latent TB part of this protocol who:
-Have documented evidence of a positive purified protein derivative (PPD) skin test or Interferon-gamma Release Assays (IGRA) test meeting American Thoracic Society (ATS)/CDC guidelines for latent TB; conversion can have occurred at any time.
FOR PATIENTS WITH ACTIVE TB
In addition to the above-described inclusion criteria for all patients, patients may be included in the Active TB part of this protocol who:
EXCLUSION CRITERIA:
Patients will be excluded from this study who:
150 participants in 2 patient groups
Loading...
Central trial contact
Carla D Williams, R.N.; Steven M Holland, M.D.
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal